alpha-mannosidosis-market

Alpha Mannosidosis Market By Indication Type (Type I, Type II, Type III), By Treatment (Bone Marrow Treatment, Enzyme Replacement Treatment) - Growth, Future Prospects, And Competitive Analysis, 2021 -2029

10 Oct 2018 Format PDF icon PPT icon XLS icon Request Sample

Aplha mannosidosis is a rare genetic disorder belonging to a group of diseases known as lysosomal storage disorders. Aplha mannosidosis occurs in 1 in every 500,000 people in the general population and is characterized by a deficiency of the enzyme alpha-D-mannosidase. The symptoms, progression and severity of alpha-mannosidosis vary widely from one person to another, including between siblings who share the same mutation.

The report titled “Global Alpha Mannosidosis Market- Growth, Future Prospects and Competitive Analysis, 2021–2029” offers strategic insights into the alpha mannosidosis market along with the market size and estimates for the duration 2021 to 2029. The research study covers in-depth analysis of market segments based on Indication type, treatment and different geographical region.

Alpha Mannosidosis Market

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in global alpha mannosidosis market, attractive investment proposition and market positioning of key manufacturers sections.

Market size and forecast for these regional and country level markets are presented in this study for the period 2019-2029. Market growth rates for the forecast period 2021-2029 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global alpha mannosidosis market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global alpha mannosidosis market. This report concludes with company profiles section that highlights major information about the key players engaged in global alpha mannosidosis market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report. 

Thus, the research study provides a holistic view of the global alpha mannosidosis market, offering market size and estimates for the period from 2021 to 2029, keeping in mind the above-mentioned factors.

Based on the type of Indication the global alpha mannosidosis market is segmented as follows:

  • Type I
  • Type II
  • Type III

Aplha mannosidosis is a rare genetic disorder belonging to a group of diseases known as lysosomal storage disorders. Aplha mannosidosis occurs in 1 in every 500,000 people in the general population and is characterized by a deficiency of the enzyme alpha-D-mannosidase. The symptoms, progression and severity of alpha-mannosidosis vary widely from one person to another, including between siblings who share the same mutation. The commonly seen signs of dysfunctions in the people with alpha mannosidosis include intellectual disability, skeletal abnormalities and distinctive facial features. The global alpha mannosidosis market is segmented into three separate subtypes such as mild (type I), moderate (type II) and severe (type III). The type II indication held the largest share in the global alpha mannosidosis market due to high prevalence of type II alpha mannosidosis. The Type II indication is expected to grow during the forecast period due to rising prevalence of alpha mannosidase. Moreover, ongoing clinical trials for the treatment of alpha mannosidosis would further drive the market during the forecast period.

Based on the type of treatment, the alpha mannosidosis market is segmented into:

  • Bone Marrow Transplant (BMT)
  • Enzyme Replacement Therapy (ERT)

Alpha Mannosidosis belongs to a group of diseases known as the lysosomal storage disorders. The prevalence of alpha-mannosidosis is estimated to be 1 in every 500,000 people in the general population. Alpha-mannosidosis affects men and women in equal numbers and can potentially affect individuals of any ethnic group worldwide. The treatment option for alpha mannosidosis is symptomatic and supportive. The alpha mannosidosis market on the basis of treatment has been segmented into bone marrow treatment and enzyme replacement therapy. Bone marrow treatment is under clinical trial for the treatment of alpha mannosidosis. However, BMT procedure is expensive and carries the risk of serious complications including graft-versus-host disease and other long-term effects. Enzyme replacement therapy involves replacing a missing enzyme in individuals who are deficient or lack the particular enzyme in question. Lamazym, an enzyme replacement therapy, is under the late stage of clinical trials as a potential treatment for individuals with alpha-mannosidosis. Moreover, Gene therapy is also being studied as another possible approach to therapy for some lysosomal storage disorders.

For the purpose of this study, the global alpha mannosidosis market is segmented into regional markets such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America held the largest share in the alpha mannosidosis market due increased clinical trials in the regions. After the Orphan Drugs Act passed in the U.S., the development and approval of drugs for orphan diseases has escalated. As a result, it has emerged as the biggest benefit for the pharmaceutical companies to launch orphan drugs in a fast track basis. The ERT drug for alpha mannosidosis named Lamazym has also been given the orphan drug status across Europe and the U.S. Asia Pacific is projected to grow at a fastest growth rate during the forecast period. The growth will be attributed to the rising awareness about the disease in the developing countries. Government of Australia has implemented a national plan for helping patients with rare diseases to reduce the mortality rate due to these diseases. The plan aims to raise awareness about the burden of rare diseases among patients, their impact on social life, and healthcare professionals.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Alpha Mannosidosis market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Alpha Mannosidosis market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS
Research Period  2022-2032
Base Year 2023
Forecast Period  2024-2032
Historical Year  2022
Unit  USD Million
Segmentation
Indication
  • Type I
  • Type II
  • Type III

Treatment
  • Bone Marrow Treatment
  • Enzyme Replacement Treatment

 Region Segment (2022-2032; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Alpha Mannosidosis market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Alpha Mannosidosis market?
  • Which is the largest regional market for Alpha Mannosidosis market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Alpha Mannosidosis market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Alpha Mannosidosis market worldwide?
Choose Licence Type
$4325
$6325
$12650
Why Acute
View Other Reports